Investment Thesis
ANAB is a biotech company in early commercialization with impressive 157% YoY revenue growth and improving loss metrics, but remains deeply unprofitable with -$52.9M net losses and negative operating cash flow. Strong balance sheet ($248.5M cash, no debt) provides multi-year runway, though path to profitability remains uncertain.
Strengths
- Revenue growth of 157% YoY demonstrates commercialization traction
- Exceptional balance sheet with $248.5M cash and zero debt, providing substantial financial cushion
- EPS improvement of 91% YoY shows losses are decelerating relative to growth trajectory
Risks
- Company is deeply unprofitable with -$206.9% net margin and -$34.6M operating loss on $25.6M revenue
- Negative operating cash flow of -$25.9M indicates company must burn existing cash reserves despite revenue gains
- Stockholders equity of only $12.7M is minimal relative to cumulative losses, leaving limited equity cushion
Key Metrics to Watch
- Quarterly revenue growth sustainability and gross margin realization at scale
- Operating cash flow trend - critical inflection point toward positive FCF
- Operating expense ratio relative to revenue - path to breakeven profitability
Financial Metrics
Revenue
25.6M
Net Income
-52.9M
EPS (Diluted)
$-1.84
Free Cash Flow
-25.9M
Total Assets
329.7M
Cash
248.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-135.5%
Net Margin
-206.9%
ROE
-414.9%
ROA
-16.0%
FCF Margin
-101.5%
Balance Sheet & Liquidity
Current Ratio
7.58x
Quick Ratio
7.58x
Debt/Equity
0.00x
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T06:41:57.302703 |
Data as of: 2026-03-31 |
Powered by Claude AI